Filter
607
Text search:
pharmaceutical
regulatory
authority
Featured
52
198
Language
Document type
335
104
88
34
26
8
5
4
2
1
Countries / Regions
36
31
25
24
20
17
17
16
16
15
15
13
11
10
10
10
9
8
8
8
7
7
6
5
5
5
5
4
4
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
325
33
19
14
9
8
3
Toolboxes
88
81
30
23
22
19
17
9
6
6
6
5
4
3
3
3
2
2
1
1
A series of tools and templates have been developed by WHO, FAO and OIE to accompany the manual for developing national action plans on antimicrobial resistance
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Bull World Health Organ 2017;95:594–598
Selection and Use of Essential Medicines 2021
recommended
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo
...
Prepared for the Stunting Prevention and Reduction Project - The project Medical Waste Management Plan’s (MWMP) overall objective is to prevent and/or mitigate the negative effects of increased generation of medical waste on human health and the environment. The plan proposes measures to prevent t
...
Conducted November 2011 to February 2012: Summary Report
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle ...
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle ...
Strategic Overview
